Quality improvement in inflammatory bowel disease.

Management of Crohn's disease - are guidelines transferred to clinical practice? United European Gastroenterol J (2015) 0.81

Continuing Medical Education Improves Gastroenterologists' Compliance with Inflammatory Bowel Disease Quality Measures. Dig Dis Sci (2016) 0.80

Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Dig Dis Sci (2016) 0.80

Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures. Inflamm Bowel Dis (2016) 0.80

Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. PLoS One (2016) 0.75

Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res (2016) 0.75

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. Ann Gastroenterol (2016) 0.75

Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. Inflamm Bowel Dis (2016) 0.75

Quality of care in Crohn's disease. World J Gastrointest Pathophysiol (2014) 0.75

The Technical Quality of Delivered Care for People with Inflammatory Bowel Disease in Tabriz Gastroenterology Clinics. Health Promot Perspect (2015) 0.75

Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol (2017) 0.75

The quality of health care delivered to adults in the United States. N Engl J Med (2003) 50.33

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology (2004) 14.78

Who is at greatest risk for receiving poor-quality health care? N Engl J Med (2006) 6.69

Quality of health care. Part 2: measuring quality of care. N Engl J Med (1996) 6.46

The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol (2007) 6.19

Care in U.S. hospitals--the Hospital Quality Alliance program. N Engl J Med (2005) 5.74

Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet (2010) 5.63

Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15

Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology (2008) 3.79

Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2004) 3.63

European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08

Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc (2007) 2.82

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80

ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis (2011) 2.19

Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics (2012) 2.16

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol (2006) 2.12

Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.09

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology (2012) 1.97

The role of outcomes in quality assessment and assurance. QRB Qual Rev Bull (1992) 1.97

Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol (2003) 1.80

Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol (2000) 1.74

Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis (2011) 1.71

Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70

Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol (2005) 1.68

Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56

Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis (2011) 1.46

Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol (2008) 1.44

Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci (1989) 1.42

Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis (2007) 1.37

Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33

Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23

Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther (2007) 1.23

Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis (2007) 1.17

The burden of inflammatory bowel disease in the United States: a moving target? Clin Gastroenterol Hepatol (2007) 1.17

Cost of illness of Crohn's disease. Pharmacoeconomics (2002) 1.09

Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol (2008) 1.08

Development of process and outcome measures for improvement: lessons learned in a quality improvement collaborative for pediatric inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.07

Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.02

A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol (2013) 0.96

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95

The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol (2011) 0.91

An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol (2011) 0.88

Prevalence of lower extremity venous disease in inflammatory bowel disease. Int Angiol (2007) 0.80

Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97

An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71

Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57

Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies. Am J Surg Pathol (2009) 1.29

Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol (2012) 1.23

Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis (2009) 1.19

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15

Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.15

Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13

A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis (2013) 1.12

Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11

Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol (2008) 1.08

Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis (2014) 1.05

Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis (2013) 1.00

Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95

Improving quality of care in IBD: a STEEEP challenge. Inflamm Bowel Dis (2010) 0.90

The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci (2009) 0.89

Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease. Gastroenterol Clin North Am (2012) 0.88

Embracing the internet for progress in shared decision-making. Inflamm Bowel Dis (2007) 0.87

Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion (2009) 0.87

Should rare complications of treatment influence decision-making in ulcerative colitis? Inflamm Bowel Dis (2007) 0.86

The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis (2014) 0.86

A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis (2010) 0.85

Knowledge, Attitudes, and Beliefs Regarding the Role of Nutrition in IBD Among Patients and Providers. Inflamm Bowel Dis (2016) 0.84

Implementing quality measures for inflammatory bowel disease. Curr Gastroenterol Rep (2015) 0.82

Is chronic pain an extraintestinal manifestation of IBD? Inflamm Bowel Dis (2009) 0.80

Increasing Patient Activation Could Improve Outcomes for Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.78

Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. Dig Dis Sci (2015) 0.78

Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology (2009) 0.78

Foam preparations for the treatment of ulcerative colitis. Curr Drug Deliv (2012) 0.77

Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis (2010) 0.76

Give me prednisone and give me death. Inflamm Bowel Dis (2009) 0.75

IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis (2015) 0.75

Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group. Gastroenterol Hepatol (N Y) (2008) 0.75

Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Inflamm Bowel Dis (2017) 0.75

IBD LIVE case series-case 1: smoking, a controversial but effective treatment for ulcerative colitis. Inflamm Bowel Dis (2014) 0.75

IBD LIVE Case Series-Case 6. Inflamm Bowel Dis (2016) 0.75

Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. Inflamm Bowel Dis (2016) 0.75

A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. J Clin Gastroenterol (2017) 0.75

IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. Inflamm Bowel Dis (2017) 0.75

Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. Expert Rev Gastroenterol Hepatol (2012) 0.75

IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Patient with Crohn's Disease: You Hear Hoof Beats and Discover a Zebra. Inflamm Bowel Dis (2016) 0.75

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis (2016) 0.75

Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis. J Clin Gastroenterol (2016) 0.75

Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. Inflamm Bowel Dis (2017) 0.75

IBD LIVE Case Series-Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial. Inflamm Bowel Dis (2015) 0.75

Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis (2016) 0.75

IBD LIVE Series-Case 7: The Brain-Gut Connection and the Importance of Integrated Care in IBD. Inflamm Bowel Dis (2017) 0.75

Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. Dig Dis (2017) 0.75

Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2017) 0.75

Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis (2016) 0.75